Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSK3B | P49841 | 20/20 | 0.53 |
| ▸ | CYP1A2 | P05177 | 7/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.44 |
| ▸ | CYP2D6 | P10635 | 9/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11904937 | 0.91 | GSK3B (0.48) | GSK3BCYP1A2CYP3A4CYP2D6 | |
| SCHEMBL9944040 | 0.90 | GSK3B (0.64) | GSK3BCYP1A2CYP3A4CYP2D6 | |
| SCHEMBL11905022 | 0.89 | GSK3B (0.50) | GSK3BCYP1A2CYP3A4CYP2D6 | |
| SCHEMBL9943939 | 0.88 | GSK3B (0.51) | GSK3BCYP1A2CYP3A4CYP2D6 | |
| SCHEMBL11904985 | 0.85 | GSK3B (0.58) | GSK3BCYP1A2CYP3A4CYP2D6 | |
| SCHEMBL9943987 | 0.84 | GSK3B (0.52) | GSK3BCYP1A2CYP3A4CYP2D6 | |
| SCHEMBL9943951 | 0.83 | GSK3B (0.53) | GSK3BCYP1A2CYP3A4CYP2D6 | |
| SCHEMBL11904923 | 0.83 | GSK3B (0.49) | GSK3BCYP1A2CYP3A4CYP2D6 | |
| SCHEMBL11905302 | 0.83 | GSK3B (0.61) | GSK3BCYP1A2CYP3A4CYP2D6 | |
| SCHEMBL11905963 | 0.82 | GSK3B (0.46) | GSK3BCYP1A2CYP3A4CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9006232-B2 | Pyrimidone derivatives | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2015-04-14 | — | — | US | disclosed |
| US-9006232-B2 | Pyrimidone derivatives | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2015-04-14 | — | — | US | disclosed |
| US-9006232-B2 | Pyrimidone derivatives | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2015-04-14 | — | — | US | disclosed |
| US-20120208797-A1 | PYRIMIDONE DERIVATIVES | SANOFI (FR) | 2012-08-16 | — | — | US | disclosed |
| US-20120208797-A1 | PYRIMIDONE DERIVATIVES | SANOFI (FR) | 2012-08-16 | — | — | US | disclosed |
| US-20120208797-A1 | PYRIMIDONE DERIVATIVES | SANOFI (FR) | 2012-08-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120208797-A1 | PYRIMIDONE DERIVATIVES | PSEN1, PRNP, PSEN2 | GSK3B 256/4885CYP1A2 3190/4885CYP3A4 4547/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.